The FDA cleared an investigational new drug application for NTX-1024 ophthalmic solution in vernal keratoconjunctivitis, paving the way for a phase 2/3 clinical trial, according to a press release from NexEos Bio.
A randomized, double-masked, vehicle-controlled trial that will test the safety and efficacy of the eye drop is planned to begin later this year, according to the release.
According to NexEos, NTX-1024 neutralizes the eosinophil cationic protein-mediated inflammation that is involved in vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis.
“To our knowledge, NTX-1024 is